The B-Subunit of Cholera Toxin Induces Immunoregulatory Cells and Prevents Diabetes in the NOD Mouse

The B-subunit of the cholera toxin molecule (CT-B) has T-cell immunomodulatory properties. Because the pathogenesis of diabetes in the nonobese diabetic (NOD) mouse model of IDDM is thought to be a Tcell-mediated process due to an imbalance of immunoregulatory and anti-islet effector cells, we examined the effect of CT-B administration on the development of diabetes in the NOD mouse and assessed whether this potential diabetes-sparing effect of CT-B is mediated by changes in immunoregulatory and/or anti-islet cytotoxic effector cell activity. The administration of either intravenous or intraperitoneal CT-B decreased the development of diabetes with no apparent drug toxicity. At 6 months of age, only 18% of CT-B vs. 75% of saline-treated animals had diabetes. Histopathological examination revealed less islet atrophy in CT-B-treated animals. The in vitro proliferative responses of mononuclear splenocytes and thymocytes to concanavalin A and lipolysaccharide and the proportion of B-cells and T-cell subsets were not altered by CT-B treatment. CT-B administration did not inhibit the primary immunization of mice to tetanus toxoid. The development of diabetes in irradiated NOD mice was slower in the animals injected with spleen cells (SC) from CT-B–treated than from saline-treated NOD mice, suggesting that CT-B decreases anti-islet effector cell activity. The injection of SC from CT-B–treated mice inhibited the adoptive transfer of diabetes by SC from diabetic mice into irradiated NOD mice, documenting that CT-B administration induces regulatory cell activity. In conclusion, CT-B administration prevents the development of diabetes in NOD mice by inhibiting the immune destruction of islets. This islet-sparing activity appears mediated, at least in part, by the induction of regulatory cells and, in turn, suppression of anti-islet effector cells, which is not associated with generalized immunosuppression or T- or B-cell depletion.

[1]  V. Soldatenkov,et al.  Differential induction of programmed cell death in CD8+ and CD4+ T cells by the B subunit of cholera toxin. , 1996, Cellular immunology.

[2]  L. Bergelson Serum gangliosides as endogenous immunomodulators. , 1995, Immunology today.

[3]  T. Kanematsu,et al.  Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. , 1993, Transplantation.

[4]  M. Sadelain,et al.  Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. , 1993, Journal of immunology.

[5]  M. Matsumoto,et al.  Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice. , 1991, Cellular immunology.

[6]  M. Hadzija,et al.  Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice. Evidence for thymic T cell anergy that correlates with the onset of insulitis. , 1991, Journal of immunology.

[7]  M. Sadelain,et al.  Prevention of Type I Diabetes in NOD Mice by Adjuvant Immunotherapy , 1990, Diabetes.

[8]  A. Hayward,et al.  Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. , 1989, Journal of immunology.

[9]  E. Leiter,et al.  Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. , 1988, Journal of immunology.

[10]  L. Wicker,et al.  Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. , 1988, Journal of immunology.

[11]  C. Elson,et al.  Inhibition of murine lymphocyte proliferation by the B subunit of cholera toxin. , 1987, Journal of immunology.

[12]  T. Hanafusa,et al.  Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. , 1985, Clinical and experimental immunology.

[13]  Y. Tochino,et al.  The inhibitory effect of neonatal thymectomy on the incidence of insulitis in non-obese diabetes (NOD) mice , 1985 .

[14]  A. Laupacis,et al.  Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. , 1984, Science.

[15]  T. Fujita,et al.  LYMPHOCYTIC INSULITIS IN A ‘NON-OBESE DIABETIC (NOD)’ STRAIN OF MICE: AN IMMUNOHISTOCHEMICAL AND ELECTRON MICROSCOPE INVESTIGATION , 1982 .

[16]  J. Holmgren Actions of cholera toxin and the prevention and treatment of cholera , 1981, Nature.

[17]  Y. Tochino,et al.  Breeding of a non-obese, diabetic strain of mice. , 1980, Jikken dobutsu. Experimental animals.

[18]  J. Holmgren,et al.  INTERACTION OF CHOLERA TOXIN AND TOXIN DERIVATIVES WITH LYMPHOCYTES , 1974, The Journal of experimental medicine.

[19]  M. Dobersen Humoral autoimmune aspects of insulin-dependent (type I) diabetes mellitus. , 1985, Concepts in immunopathology.

[20]  W. Gepts Role of cellular immunity in the pathogenesis of type I diabetes. , 1983, Current problems in clinical biochemistry.

[21]  C. Lai The chemistry and biology of cholera toxin. , 1980, CRC critical reviews in biochemistry.